Tolerance induction with intravenous IFNβ-1a
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Mitoxantrone
What it measured
Main measures
Proof of concept study to assess the safety and immunological effects of high dose intravenous IFNβ-1a human serum albumin-free formulation (Rebif® New Formulation or RNF) after a transient, peripheral leukocyte depletion with Mitoxantrone with the objective to tolerize patients with NAbs to IFNβ.
Safety
Who could take part
MS (type not specified)
Inclusion: Inclusion criteria: Exclusion: Exclusion criteria:
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Perform a “proof-of-concept” phase IIa clinical trial to induce tolerance to IFNβ in subjects with NAbs to IFNβ-1a.
Loading reviews and guidelines…
Related trials
- COVID-19 Booster Vaccine in Autoimmune Disease Non-Respon…
Phase 2 · Stopped early
Stopped early
- Clinical and Imaging Cohort of Neuroinflammation Diseases…
Recruiting
Still running
- AUTOLOUGUS STEM CELLS TRANSPLANTATION IN SM
Phase 1 · —
No result found
- High Dose Chemo With Stem Cell Transplant as Treatment fo…
Phase 2 · Stopped early
Stopped early
- MITOX-REBIF
Phase 3 · Completed
No result found
- IQUALYSEP
Not a drug-phase study · Completed
No result found
History
Started
Dec 2010
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error